Is AGE accumulation a therapeutic target for diabetic complications?

Netherlands Journal of Medicine

Volumn 64, Issue 1, 2006, Pages 1-3

  Huijberts, M S P ^a   Schalkwijk, C G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; METFORMIN; PROTEIN KINASE C; PYRIDOXAMINE; THIAMINE;

ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; IMMUNOASSAY; LIPID PEROXIDATION; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SIDE EFFECT;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN;

EID: 31644446684     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-25.
2. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005;67:3-21.
3. Mentink CJ, Kilhovd BK, Rondas-Colbers GJ, Torjesen PA, Wolffenbuttel BH. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth J Med 2006;64(1):10-6.
4. Teerlink T, Barto R, ten Brink HJ, Schalkwijk CG. Measurement of N{epsilon}-(Carboxymethyl)lysine and N{epsilon}-(Carboxyethyl)lysine in Human Plasma Protein by Stable-Isotope-Dilution Tandem Mass Spectrometry. Clin Chem 2004;19:910-6.
5. Anderson MM, Heinecke JW. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003;52:2137-43.
6. Monnier VM. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003;419:1-15.
7. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31-40.
8. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003;29:95-103.
9. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci 2005;1043:807-16.
10. Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004;19:336-40.
11. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin Converting Enzyme-1 Inhibition in Diabetic Nephropathy. J Am Soc Nephrol 2005;16:2363-72.